Midatech Pharma Plc Gross margin

What is the Gross margin of Midatech Pharma Plc?

The Gross margin of Midatech Pharma Plc is -630.90%

What is the definition of Gross margin?



Gross margin is the difference between revenue and cost of goods sold, divided by revenue, and expressed as a percentage.

lfy (last fiscal year)

Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.

Gross margin of companies in the Health Care sector on LSE compared to Midatech Pharma Plc

What does Midatech Pharma Plc do?

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Companies with gross margin similar to Midatech Pharma Plc